AstraZeneca has completed an exclusive global license agreement with KYM Biosciences Inc.i for CMG901, a potential first-in-class antibody drug conjugate targeting Claudin 18.2, the company announced. "CMG901 is currently being evaluated in a Phase I trial for the treatment of Claudin 18.2-positive solid tumours, including gastric cancer. Preliminary results from the trial have shown an encouraging profile for CMG901, with early signs of anti-tumour activity across the dose levels tested. AstraZeneca has entered into an exclusive global license for the research, development, manufacture and commercialisation of CMG901 for an upfront payment of $63M, with potential development and sales-related milestone payments of up to $1.1B and tiered royalties up to low double digits. The transaction does not impact AstraZeneca’s financial guidance for 2023," the company stated.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AZN:
- Oppenheimer emerging biotech analyst to hold analyst/industry conference call
- Ionis Pharmaceuticals announces NEURO-TTRansform study met co-primary endpoints
- AstraZeneca says Calquence conditionally approved in China for first indication
- JPMorgan biotech/pharma analysts to hold KOL analyst/industry conference call
- AstraZeneca price target lowered to 124 GBp from 126 GBp at Berenberg
